You are a subscriber
If you are not already a subscriber,
Choose a subscription offer and create your account to read all content on MediapartCreate your account
French pharma giant Sanofi Aventis has been placed under investigation for suspected manslaughter in a judicial probe into the marketing of its epilepsy treatment drug Depakine, which a public watchdog has estimated caused up to 450 babies to be stillborn or contract congenital birth defects in France between 2006 and 2014.
Reading articles is for subscribers only. Subscribe now.